Trial Profile
Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Glioma
- Focus Biomarker; Pharmacokinetics; Therapeutic Use
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Nov 2011 Trial lead investigator identified as reported by ClinicalTrials.gov.
- 17 Nov 2011 Company (Genzyme Corporation) added as trial affiliate as reported by ClinicalTrials.gov.